HAMAMATSU CITY, Japan, Jan. 29, 2020 /PRNewswire/ — By applying its own unique microelectro-mechanical systems (MEMS) technology, Hamamatsu Photonics has successfully developed a palm-sized “Fourier transform infrared spectrometer (FTIR) engine C15511-01” offering high sensitivity to near-infrared light at wavelengths from 1.1 to 2.5 micrometers (abbreviated to μm: μ is one millionth). This FT-IR engine will assist in creating portable handheld FTIR spectrophotometers for analytical applications including real-time monitoring of chemicals on production lines and ingredient analysis of agricultural products in the field. Hamamatsu Photonics will start accepting product orders from analytical instrument manufacturers from Monday, February 3rd, 2020.
This FTIR engine will be on display at the exhibition running in parallel to the International Conference “SPIE Photonics West 2020” held in San Francisco, California, United States, for 3 days from February 4th to February 6th.
To access the full article, please follow the below link:
https://www.hamamatsu.com/eu/en/news/product_technology/2020/20200128000000.html
Photo – http://blog.m.healthtechnologynet.com/wp-content/uploads/2020/01/FTIR_C15511.jpg
For further information contact us on email: europe@hamamatsu.de or visit our website: www.hamamatsu.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/hamamatsu-photonics-has-developed-a-palm-sized-ftir-engine-capable-of-highly-sensitive-detection-of-near-infrared-light-at-wavelengths-ranging-from-1-1-to-2-5-micrometers-300995227.html
SOURCE Hamamatsu Photonics Europe GmbH
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK…
The study met its primary endpoint of overall survival with a 41% reduction in the…
DENVER, CO / ACCESSWIRE / June 15, 2024 / Each year over 120,000 Coloradans are…
REYKJAVIK, Iceland, June 15, 2024 /PRNewswire/ -- In a recent display of global baking talent,…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha-…